|
|
| | PF-06700841-TsOH Basic information |
| Product Name: | PF-06700841-TsOH | | Synonyms: | PF-06700841-TsOH;PF-06700841 free base;CS-2860;PF-06700841 P-TOSYLATE;Brepocitinib (P-Tosylate);Janus kinase,JAK,Brepocitinib P-Tosylate,inhibit,Brepocitinib PTosylate,Inhibitor,Brepocitinib P Tosylate;PF 06700841-15;((S)-2,2-Difluorocyclopropyl)(3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone 4-methylbenzenesulfonate | | CAS: | 2140301-96-6 | | MF: | C25H29F2N7O4S | | MW: | 561.61 | | EINECS: | | | Product Categories: | API | | Mol File: | 2140301-96-6.mol |  |
| | PF-06700841-TsOH Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 10 mg/ml; DMSO: 10 mg/ml; DMSO:PBS (pH 7.2) (1:20): 50μg/ml; Ethanol: slightly soluble | | form | A crystalline solid | | color | White to off-white | | InChIKey | FAKGOYNHHHOTEN-QYGWXNHUNA-N | | SMILES | S(C1C=CC(C)=CC=1)(O)(=O)=O.C([C@@H]1CC1(F)F)(N1C2CCC1CN(C1C=CN=C(NC3=CN(C)N=C3)N=1)C2)=O |&1:12,r| |
| | PF-06700841-TsOH Usage And Synthesis |
| Uses | Brepocitinib (PF-06700841) P-Tosylate is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively[1]. | | in vivo | Brepocitinib (Compound 23; 3-30 mg/kg; oral administration; for 7 consecutive days; female Lewis rats) treatment significantly reduces paw volume increase in a dose-dependent manner. The plasma concentrations in animals dosed with Brepocitinib at peak (30 min) and trough (24 h) time intervals post final dose respectively are as follows: 3 mg/kg, 3.54 μM, 0.0221 μM; 10 mg/kg, 10.95 μM, 0.06 μM; and 30 mg/kg, 23.89 μM, 0.06 μM[1]. | Animal Model: | Female Lewis rats with induced arthritis[1] | | Dosage: | 3 mg/kg, 10 mg/kg, or 30 mg/kg | | Administration: | Oral administration; for 7 consecutive days | | Result: | Increased in paw volume was significantly lower and dose-dependent.
|
| | IC 50 | JAK1: 17 nM (IC50); JAK2: 77 nM (IC50); JAK3: 6.9 μM (IC50) | | References | [1] Fensome A, et al. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700 DOI:10.1021/acs.jmedchem.8b00917 |
| | PF-06700841-TsOH Preparation Products And Raw materials |
|